Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 13 Issue 2, February 2013

Research Highlight

  • Jeffrey Wrana and colleagues find that exosomes from cancer-associated fibroblasts activate WNT–planar cell polarity signalling in recipient breast tumour cells, which promotes motility and metastasis.

    • Gemma K. Alderton
    Research Highlight

    Advertisement

  • The tumour suppressor neurofibromatosis type 2 (NF2) restricts ezrin localization to establish cortical asymmetry and correctly position centrosomes and spindles during cell division in polarized epithelial cells.

    • Sarah Seton-Rogers
    Research Highlight
  • Susan Clark and colleagues have found evidence in cancer cells that epigenetic changes can occur over long stretches of chromatin, leading to increased gene expression.

    • Nicola McCarthy
    Research Highlight
  • This paper finds that secreted chromatin fragments from leukaemia cells activate DNA damage responses in recipient stromal cells, which leads to their death.

    • Gemma K. Alderton
    Research Highlight
  • Karen Vousden and colleagues have found that cancer cells that have lost the expression of the tumour suppressor p53 are unable to adapt in conditions of serine starvation.

    • Nicola McCarthy
    Research Highlight
  • Joan Massagué and colleagues have found that epigenetic changes contribute to metastasis in clear-cell renal-cell carcinomas in which the tumour suppressor gene von Hippel–Lindau (VHL) is inactivated.

    • Nicola McCarthy
    Research Highlight
Top of page ⤴

In the News

  • A new study suggests that positive results of breast cancer clinical trials are being exaggerated and side effects downplayed.

    • Catriona Rodwell
    In the News
Top of page ⤴

Research Highlight

  • Two studies now describe new approaches to targeting anti-apoptotic BCL-2 family members in various cancer types.

    • Darren J. Burgess
    Research Highlight
  • Two new studies identify inhibitors of MALT1 that show anticancer activityin vitro and in vivofor an aggressive subtype of lymphoma.

    • Darren J. Burgess
    Research Highlight
  • WNT signalling has been linked to the transcriptional coactivators TAZ and YAP1.

    • Nicola McCarthy
    Research Highlight
Top of page ⤴

In Brief

Top of page ⤴

Review Article

  • The reactivation of wild-type p53 could potentially improve the treatment of many cancer patients. One strategy to achieve this is to target the p53 regulators MDM2 and MDMX. This Review discusses our understanding of how these proteins regulate p53 and the progress that has been made in targeting them.

    • Mark Wade
    • Yao-Cheng Li
    • Geoffrey M. Wahl
    Review Article
  • Epithelial to mesenchymal transition (EMT) is essential for driving plasticity during development, but can also occur in tumour cells during cancer progression. This Review discusses the layers of regulation (including the transcriptional and translational machinery, non-coding RNAs, alternative splicing and protein stability) that control the process and plasticity of EMT.

    • Bram De Craene
    • Geert Berx
    Review Article
  • LIM-domain-only (LMO) proteins are a subset of the LIM-domain protein family and function primarily as transcriptional regulators. They are associated with various cancers, including T cell acute lymphoblastic leukaemia (T-ALL) that resulted from unintended activation ofLMO2by insertional mutagenesis in human gene therapy trials. This Review discusses the roles and potential mechanisms of LMO proteins in cancer and the potential for therapeutic targeting.

    • Jacqueline M. Matthews
    • Krystal Lester
    • David J. Curtis
    Review Article
  • Hepatocellular carcinoma (HCC) is mainly associated with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections. This Review outlines pathogenic mechanisms that seem to be common to both HBV and HCV, in the hope that this might suggest innovative approaches for the prevention and treatment of HCC.

    • Alla Arzumanyan
    • Helena M. G. P. V. Reis
    • Mark A. Feitelson
    Review Article
Top of page ⤴

Opinion

Top of page ⤴

Search

Quick links